Loading organizations...
§ Private Profile · Cambridge, MA, USA
Merida Biosciences is a technology company.
Merida Biosciences focuses on precision therapy for autoimmune-driven diseases, aiming to target and eliminate pathogenic drivers with unprecedented precision.
Merida Biosciences has raised $120.0M across 1 funding round.
Merida Biosciences has raised $120.0M in total across 1 funding round.
Merida Biosciences has raised $120.0M across 1 funding round. Most recently, it raised $120.0M Series A in April 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2025 | $120M Series A | Bain Capital Life Sciences, Third Rock Ventures, BVF Partners | — | Announced |
Merida Biosciences has raised $120.0M in total across 1 funding round.
Merida Biosciences's investors include Bain Capital Life Sciences, Third Rock Ventures, BVF Partners.
Merida Biosciences is a biotechnology company developing precision Fc biotherapeutics that selectively eliminate pathogenic autoantibodies driving autoimmune and allergic diseases, without broad immunosuppression.[1][2][5] Its lead program targets Graves’ disease, aiming to neutralize disease-causing autoantibodies to restore thyroid function, while additional pipeline candidates address IgE-mediated allergies (e.g., food allergies) and primary membranous nephropathy, a kidney disorder linked to anti-PLA2R autoantibodies.[1][2][6] Launched in April 2025 with $121 million in Series A funding from Third Rock Ventures, Bain Capital Life Sciences, BVF Partners, GV, and PXV Funds, Merida serves patients with antibody-driven immune disorders, solving the limitations of current non-specific treatments that often yield poor efficacy and serious side effects.[1][2][5] The company, based in Cambridge, Massachusetts, and led by CEO Adam Townsend, is advancing its Graves’ program to IND-enabling studies, with preclinical proof-of-concept underway for others, positioning it for rapid clinical momentum.[1][2][6]
Merida Biosciences was seeded in 2022 by Third Rock Ventures and officially launched in April 2025 with its $121M Series A, marking a pivotal emergence in precision immunology.[1][2] CEO Adam Townsend leads the effort, leveraging antibody engineering expertise to pioneer Fc biotherapeutics designed with AI assistance for dual action: depleting autoantibodies via liver degradation and blocking pathogenic B cells.[2][6] The idea stemmed from unmet needs in autoimmune treatments—current options like thyroid surgery or radioactive iodine for Graves’ are intrusive—prompting Merida's platform to target root causes precisely.[1][5] Early traction includes strong investor backing from top VCs and a robust team of scientists and executives, including VPs in discovery, clinical development, and regulatory affairs, setting the stage for IND filing in Graves’ disease this year.[1][4][6]
Merida stands out through its proprietary Fc biotherapeutics platform, engineered for high selectivity and durability:
Merida rides the precision immunology wave, capitalizing on advances in protein engineering and AI to shift autoimmune treatments from symptom management to root-cause elimination amid a market demanding safer, more effective biologics.[5][6] Timing aligns with surging demand—autoimmune diseases affect millions, yet therapies like steroids or organ ablation remain crude—fueled by investor enthusiasm for platforms like Merida's, evidenced by its oversized Series A.[1][2] Market forces favoring it include regulatory tailwinds for orphan indications like Graves’ and membranous nephropathy, plus expanding allergy pipelines amid rising food allergy prevalence.[1][6] Merida influences the ecosystem by validating FcγRIIB-targeted therapies, potentially inspiring competitors and attracting partnerships, while its Third Rock origins amplify network effects in Boston's biotech hub.[1][4]
Merida is primed to file its IND for the Graves’ program imminently, entering clinical trials in 2026 with potential to disrupt thyroid disease care, followed by allergy and kidney readouts.[1][6] Key trends like AI-driven biologics design and precision med expansion will accelerate its pipeline across dozens of indications, bolstered by $121M runway for Phase 1/2 data.[2][5][6] Influence may evolve via buyouts from big pharma eyeing immunology platforms or further funding to lead in "antibody-like" therapies, ultimately delivering the durable responses that redefine patient outcomes in antibody-driven diseases.[1][5] This positions Merida as a high-momentum biotech tackling immunology's root causes head-on.